Press Releases


Press releases and abstracts for each press conference presentation are available at these links:

Updated monarchE Trial Data Shows Abemaciclib Continues to Benefit Patients With High-risk, HR-positive, HER2-negative, Early-stage Breast Cancer

Postmenopausal Women With Early-stage Breast Cancer and Low Recurrence Score Could Skip Adjuvant Chemotherapy

Under-recognition of Symptoms May Be Common in Patients With Breast Cancer Receiving Radiotherapy

Women Who Undergo Mastectomy and Reconstructive Surgery May Be at Risk of Becoming Persistent Drug Users

Circulating Tumor Cell Dynamics May Predict Treatment Response and Prognosis in Patients with Metastatic Breast Cancer

Omitting Radiation Therapy After Breast-Conserving Surgery May Not Impact 10-year Survival Rates for Older Patients With HR-positive Breast Cancer

Breast Cancer Survivors Are Less Likely to Get Pregnant, but Often Have Healthy Babies and Good Long-term Health

Please note that in some cases, data may have been updated since the abstracts were submitted. The press releases contain the most up-to-date information.


Breast cancer researcher to receive memorial lecture award

Researchers to be honored at San Antonio Breast Cancer Symposium

The 2019 San Antonio Breast Cancer Symposium: What to Expect

Breast Cancer Meeting ‘Is Going to Be Spectacular’

Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer

FDA Pipeline: Treatments for HER2-Positive Breast Cancer, AML; Breakthrough Device for Prostate Cancer; Statement on Safety Information for Breast Implants

San Antonio medical school gets millions to research breast cancer

Adjuvant T-DM1 Approaches EU Approval for HER2+ Early Breast Cancer

MacroGenics’ Metastatic Breast Cancer Drug Shows Survival Benefits in Phase III Trial

Tucatinib Shows Positive Results in Pivotal Trial in Locally Advanced HER2+ Breast Cancer

Novel Anti-HER2 Agents Look to Change Practice at SABCS

Five Key Studies at the San Antonio Breast Cancer Symposium 2019 Conference

Retrospective review: Proton therapy well tolerated in patients undergoing breast conserving surgery

Press Program Coverage

December 11, 2019

New HER2 Antibody-drug Conjugate Yielded Promising Clinical Responses in Breast Cancer Patients Pretreated with T-DM1

  • The New York Times
  • Los Angeles Times
  • US News & World Report
  • ABC News

Advisory: Adding Tucatinib to Trastuzumab and Chemotherapy Improves Survival for Patients with Metastatic HER2-Positive Breast Cancer

Addition of S-1 to Post-operative Endocrine Therapy Improves Outcomes for Patients with Hormone Receptor-positive, HER2-negative Breast Cancer

Updated APHINITY Trial Data Show Addition of Pertuzumab to Trastuzumab Plus Chemotherapy Continues to Yield Clinical Benefit in Patients With Operable HER2-positive Early Breast Cancer

Combining Endocrine Therapy with a CDK4/6 Inhibitor Results In Similar Response Rates to Chemotherapy for High-Risk Luminal B Breast Cancer

December 12, 2019

Neoadjuvant Treatment with Pembrolizumab Improves Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer with Lymph Node Involvement

Combining Atezolizumab with Neoadjuvant Chemotherapy Does Not Improve Pathologic Complete Response Rates for Patients with Triple-Negative Breast Cancer

Breast Cancer Preventive Effects of Anastrozole Persist Long After Stopping Treatment

Partial Breast Irradiation May be as Effective as Whole Breast Irradiation in Preventing Recurrence in Patients with Early Breast Cancer

MINDACT Trial Data Reveal Certain Women With Luminal Breast Cancer May Be Undertreated With Tamoxifen Alone (The decreased media coverage is due to Dr. Cardoso as a no-show for all on-site interviews.)

December 13, 2019

Long-term Follow-up Shows Estrogen Alone and Estrogen Plus Progestin Have Opposite Effects on Breast Cancer Incidence in Postmenopausal Women

Residual Cancer Burden Can Predict Outcomes for Patients With Any Breast Cancer Type

Circulating Tumor DNA May Help Predict Recurrence in Patients with Early Triple-Negative Breast Cancer

Oral Paclitaxel Yielded Better Outcomes Than Intravenous Paclitaxel for Metastatic Breast Cancer Patients in Phase III Trial

Additional SABCS Coverage

Everyday Health

Daily Mail


Pharmacy Times

Cancer Therapy Advisor

The Medical News


MedPage Today

The Cancer Letter

San Antonio Express-News

The ASCO Post



Cancer Network


The Center for Biosimilars


2018 Press 

Wednesday, December 5, 2018, Press Conference 1
7:15-7:45 a.m. CT

SABCS Co-director Carlos Arteaga, MD, director of the Harold C. Simmons Comprehensive Cancer Center at UT Southwestern Medical Center, will moderate a press conference featuring the following research:
7979 Wurzbach Road
MC 8224

San Antonio, Texas 78229, USA


Wednesday, December 5, 2018, Press Conference 2
12:15-12:45 p.m. CT

Dr. Arteaga will moderate a second press conference featuring the following research:
In collaboration with  Astro     and     SSO